Novacyt SA (LSE:NCYT) - Share price


Stock Report

Novacyt SA NCYT

Last Price
GBX285.20

Day Change
32.50|12.86%

As of 22/10/2021
17:45:13 BST | GBX
Minimum 15 Minutes Delay.

Last Close252.70p
Day Range245.60 - 294.30
Mkt Cap202.40Mil
52-Wk Range245.60 - 1,276.00
Yield %-
ISINFR0010397232
Volume1,299,129
P/E2.32
P/S0.01
P/CF0.02

Share Price

Total Returns 22/10/2021

 Chg (%)  
More ...
Novacyt SA-11.43 
FTSE 100 TR GBP1.86
 
Financials
201820192020
More ...
Income Statement
Turnover12.3711.47277.20
Operating Profit-0.47-1.06174.92
Net Profit-1.90-3.42132.42
Reported EPS-5.41-8.00194.00
Balance Sheet
Current Assets6.975.84204.99
Non Current Assets20.2820.6229.29
Total Assets29.3226.53234.28
Current Liabilities8.865.8574.14
Total Liabilities11.1614.0783.57
Total Equity18.1612.46150.71
Cash Flow
Operating Cash Flow-1.30-1.01123.55
Net Change in Cash-2.880.5189.97
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
12/11/2020PurchaseMr. Jean-Pierre Jacques Crinelli9.701,54114,948.00
11/11/2020PurchaseGraham D. Mullis817.0060,875497,349.00
10/11/2020PurchaseDr. Edwin Snape715.001,0807,722.00

Company Profile

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. Its diagnostic products are used in LBC, oncology, microbiology, hematology, and serology testing. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: Lab21 Product segment is a developer, manufacturer, and distributor of a large range of protein-based infectious disease IVD products; IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Sector

Diagnostics & Research

Index

FTSE AIM 100 , FTSE AIM All-Share

Next Event 22/06/2022

Final Results
Ratios
Comp
More ...
PER (E)2.25
Div Yld (E)0.00
PEG (E)0.00
ROCE104.15
Op Mrgn0.63
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive DirectorDr. Andrew John William Heath
Non-Executive DirectorDr. Edwin Snape
Executive Director, Chief Corporate Development Officer (CCDO). Both appointments are with immediate effect.Mr. Anthony Stephen Dyer
Non-Executive Director, ChairmanMr. James Christopher Wakefield
Non-Executive DirectorMr. Jean-Pierre Jacques Crinelli
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.